In Vitro Maturation: How IVM Differs From Standard IVF

In vitro maturation, or IVM, is a fertility technique in which immature eggs are collected from the ovaries and then brought to full maturity in a laboratory dish rather than inside the body. Unlike conventional IVF, which relies on heavy hormone injections to force many eggs to mature simultaneously before retrieval, IVM deliberately harvests eggs while they are still immature and coaxes them through their final developmental steps in culture. The technique is now classified as nonexperimental and is practiced at a growing number of specialized centers worldwide, particularly for patients who need to avoid the hormonal load of standard stimulation.

Why Eggs Need to Mature in the First Place

Human eggs spend most of their existence in a state of suspended animation. They are locked in an early stage of cell division, held there by high levels of a signaling molecule called cyclic AMP (cAMP) inside the egg cell. This biochemical brake keeps the egg from completing its division until the body sends the right hormonal signal, a surge of luteinizing hormone (LH), to release it.¹ Research has shown that human eggs maintain this arrest through a signaling pathway involving a receptor called GPR3, similar to the mechanism found in rodents.²

In conventional IVF, large doses of follicle-stimulating hormone (FSH) and then a trigger shot of human chorionic gonadotropin (hCG) or a similar drug mimic and amplify that natural LH surge in the body, pushing many eggs to mature inside their follicles before retrieval. IVM skips most of that process. Eggs are retrieved while still immature, and the final maturation steps are replicated in the lab using culture media supplemented with hormones and growth factors.

What Happens in the Lab

Once immature eggs are collected, they are placed into specially formulated culture media. Getting the recipe right has been one of the main challenges in IVM’s history. Part of the LH surge’s effect on the ovary works through epidermal growth factor (EGF) family members, particularly amphiregulin and epiregulin, which act as go-between signals in the follicle. When researchers added these molecules to IVM culture media, the proportion of human eggs reaching full maturity jumped from about 37% to 76%.³ Other growth factors, such as growth differentiation factor 9, have been shown to boost fertilization rates and embryo viability when added alongside cumulus cells (the supportive cells that naturally surround the egg).⁴ In bovine work, defined media containing EGF, IGF1, or FGF2 achieved maturation rates around 88 to 90%, on par with older undefined media containing fetal bovine serum.⁵ These animal studies have been instrumental in refining the recipes used for human eggs.

The Biphasic Approach

One of the most significant recent advances is a two-step culture system known as capacitation IVM, or CAPA-IVM. Standard IVM places immature eggs directly into maturation media, prompting them to resume their cell division immediately. The trouble is that eggs pulled from small follicles may not be ready for that sprint. CAPA-IVM adds a pre-maturation phase that briefly holds the egg in its arrested state, preserving communication between the egg and its surrounding cumulus cells, before the conventional maturation step begins.⁶

The results have been striking. CAPA-IVM doubled the percentage of good and top-quality day-3 embryos compared to standard IVM. Eggs from small follicles, under about 6 mm, benefited the most, with a significant increase in quality embryos and larger egg diameters at the end of culture.⁷ Early clinical data suggest that CAPA-IVM produces acceptable pregnancy outcomes, does not cause ovarian hyperstimulation syndrome (OHSS), and shows no concerns about child development up to two years of age.⁸

Who Benefits Most

IVM’s primary audience is patients with polycystic ovary syndrome (PCOS) or a high antral follicle count, which is the pool of small resting follicles visible on ultrasound. These patients are at the highest risk of OHSS from conventional stimulation, a potentially dangerous complication involving fluid shifts, abdominal swelling, and in severe cases, blood clots. IVM sidesteps OHSS almost entirely because it requires little to no hormonal stimulation.⁹ A recent matched cohort study of women with PCOS found no severe OHSS in the IVM group, compared to about 1% of conventional IVF cycles.¹⁰

Interestingly, women with PCOS may respond better to IVM than women without it. A meta-analysis found that PCOS patients had higher clinical pregnancy and implantation rates from IVM compared to non-PCOS patients, though maturation rates and miscarriage rates were similar between groups.¹¹ The reason for this edge is not entirely clear, but it likely relates to the large number of immature eggs available for retrieval in PCOS ovaries, giving clinicians more material to work with.

Urgent Fertility Preservation in Cancer

The other major clinical role for IVM is fertility preservation when there is no time for a full stimulation cycle. A person newly diagnosed with cancer often faces treatment that could damage their ovaries within days or weeks. Standard IVF stimulation takes roughly two weeks and requires starting at a specific point in the menstrual cycle. IVM can be performed regardless of cycle phase, a crucial advantage when timing is dictated by oncology treatment schedules. Research on breast cancer patients has shown comparable numbers of eggs recovered and similar IVM maturation rates whether retrieval happened during the follicular or luteal phase of the cycle.¹²

A systematic review and meta-analysis of IVM for cancer patients found that while maturation rates are lower than those achieved with controlled ovarian stimulation, the fertilization rates per mature egg are comparable.¹³ Put plainly, IVM produces fewer mature eggs, but each mature egg it does produce works about as well. One study also concluded that immature eggs retrieved during standard fertility preservation cycles in cancer patients should not be discarded, because they can mature in the lab at rates comparable to those of healthy women.¹⁴

How Outcomes Compare to Standard IVF

The honest picture is that IVM still trails conventional IVF in cumulative live birth rates. A 36-month matched cohort study in women with PCOS found that the cumulative live birth rate per retrieval cycle was about 22% for IVM versus 48% for IVF.¹⁵ A separate systematic review and meta-analysis of PCOS patients found no differences in fertilization rate, clinical pregnancy rate, or miscarriage between IVM and IVF, but the IVF group had a higher live birth rate overall.¹⁶

The gap narrows with frozen embryo transfers. In the same cohort study, live births after the first frozen transfer were comparable between IVM and IVF, and the IVM group actually had higher implantation rates from frozen transfers than the IVF group.¹⁷ This suggests that at least part of IVM’s lower success rate in fresh cycles may relate to how IVM affects the uterine lining rather than the embryo itself, a distinction that freezing and later transfer can bypass.

Safety for Children Born After IVM

One of the first questions any prospective parent asks is whether babies conceived through IVM are healthy. The existing data are reassuring. A study that followed IVM and IVF children born to women with PCOS found the rate of congenital anomalies was nearly identical between groups, about 4% in each, and growth and development were normal through a mean follow-up of about seven and a half years.¹⁸ An earlier comparative analysis similarly found that IVM was not associated with any additional risk of congenital abnormalities beyond those seen with IVF or intracytoplasmic sperm injection.¹⁹

Chromosome abnormality rates in embryos derived from IVM eggs also appear comparable to those from standard IVF. Multiple studies using genetic screening on embryos found no significant difference in aneuploidy between the two groups.²⁰²¹ That said, concerns about subtler effects persist. One study of the epigenetic profile of IVM eggs found that most fully matured eggs maintained normal patterns, but a minority showed altered methylation at a specific gene region, raising questions about whether lab culture conditions can sometimes leave molecular fingerprints that would not occur in the body.²² The clinical significance of these epigenetic changes remains unclear, and larger studies are needed. For now, no downstream health problems have been attributed to them.

Freezing Before or After Maturation

A practical question in fertility preservation is whether to freeze eggs before or after they have been matured in vitro. The answer, at least for human eggs, appears to favor maturing first and then freezing. One study found that the maturation rate per collected egg was about 46% when IVM was done before vitrification, but only about 24% when eggs were vitrified first and then matured after thawing.²³

Animal data present a slightly different picture. In porcine eggs, vitrification at the immature stage actually led to better cytoskeletal integrity and superior blastocyst development compared to vitrification at the mature stage, though both vitrified groups performed worse than unfrozen controls.²⁴ The discrepancy likely reflects species-specific differences in how egg cells respond to the stresses of freezing at different developmental stages. For human clinical practice, the current evidence supports maturing eggs first when possible.

The Cost Equation

Because IVM requires little or no hormonal stimulation, it is considerably cheaper per cycle than conventional IVF. A cost-effectiveness analysis in women with a high antral follicle count calculated mean costs of about €4,300 per couple for IVM compared to €6,500 for IVF. The study found that while IVM led to a slightly lower cumulative live birth rate, the incremental cost of achieving each additional live birth with IVF was roughly €20,000.²⁵ The lower medication burden also means fewer clinic visits for monitoring, less discomfort, and a shorter treatment timeline. For patients undergoing multiple cycles, these savings compound.

IVM Beyond Human Fertility

IVM plays a large and growing role in animal agriculture and conservation biology. In cattle, in vitro embryo production using IVM is widely used across North America, South America, and Europe, often combined with sexed semen and genomic selection to accelerate breeding programs. The technology allows eggs to be retrieved from a broader range of donor animals, including open cyclic cows and animals up to three months pregnant, and it reduces the number of sperm needed to produce each embryo.²⁶ Challenges remain, however, including reduced egg quality after in vitro maturation and lower tolerance for freezing compared to embryos produced entirely inside the animal.

In conservation, IVM offers a way to bank genetic material from endangered species. Researchers have applied the technique to the Mhorr gazelle, collecting immature eggs followed by in vitro maturation, fertilization, and culture to rescue biological material of high genetic value.²⁷ Work on Southern white rhinoceros has explored practical details such as warming the enema used during egg retrieval, which more than doubled the odds of successful in vitro maturation.²⁸ These programs highlight how IVM can serve as a bridge between reproductive science and species survival when natural breeding is insufficient.

Emerging Technologies Around IVM

Several frontier technologies are converging on IVM to address its remaining weaknesses. Machine learning is being used to predict which eggs will mature fastest based on non-invasive observation of morphological features like cumulus expansion rate, tested so far in cattle with promising results.²⁹ Automated microscopy systems that combine precision-controlled imaging with deep learning are being developed to continuously monitor eggs during culture without disturbing them, tracking cumulus expansion as a real-time readout of maturation progress.³⁰ On the biomarker side, analysis of gene expression in cumulus cells is being explored as a way to predict which eggs are most likely to produce viable embryos after fertilization, offering clinicians a non-invasive tool to select the best candidates.³¹

Microfluidic devices represent another frontier. Lab-on-a-chip platforms can culture individual follicles in three-dimensional hydrogel environments that more closely mimic the conditions inside the body.³² By controlling fluid flow, nutrient gradients, and mechanical support at a microscopic scale, these systems aim to recapitulate the follicular environment more faithfully than a standard culture dish can. The technology is still in early stages for human use, but the underlying concept, giving the egg a more body-like context during its maturation, aligns with the broader trajectory of IVM research: every improvement in culture conditions narrows the performance gap with eggs matured inside the body.

Looking further ahead, in vitro gametogenesis, the creation of eggs or sperm entirely from stem cells, represents a speculative but actively researched extension of the same principles. If functional eggs could be generated from a patient’s own skin or blood cells, IVM-like culture systems would likely be the final step in bringing those lab-made eggs to maturity. That possibility remains firmly in the research stage, with significant safety and ethical questions unresolved, but it illustrates how central the science of egg maturation has become to the broader future of reproductive medicine.³³